ALX cuts two anti-CD47 programs just weeks after Gilead stopped a pivotal study of its own candidate
ALX Oncology is cutting two studies of its anti-CD47 drug evorpacept after it failed to show substantial efficacy.
In its second-quarter report Thursday afternoon, ALX said that it was winding down studies of evorpacept in acute myeloid leukemia (AML) and its precursor disease, myelodysplastic syndromes (MDS). In 45 patients in the MDS study, the drug in combination with chemotherapy failed to do substantially better than chemotherapy alone, ALX said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
